Product supply updates

From time to time we may experience shortages of some products and may divest or discontinue others. The tables below provide further information on this.

For healthcare professionals who require more information about shortages, please contact MSD Ireland on +353 1 299 8700.

If you are a patient seeking information on how shortages may affect your treatment, we recommend that you consult your doctor.

For more information about our products, please call our medical information line via our switchboard on +353 1 299 8700.

_____________________________________________________________________________

NOTIFICATION

From March 2019, Keytruda (pembrolizumab) will be supplied by MSD exclusively in the form of 100 mg vial (25 mg/mL concentrate for solution for infusion) and availability of the 50 mg vial as lyophilised powder (50 mg powder for concentrate for solution for infusion) will begin to cease. At that time, remaining stocks of the 50 mg vial of Keytruda (pembrolizumab) powder for concentrate for solution for infusion may continue to be used until the stock is finished.

_____________________________________________________________________________

SINEMET

MSD has informed the Health Products Regulatory Authority (HPRA) we are anticipating a stock shortage of some SINEMET® products, a product used by patients for the treatment of Parkinson’s Disease, in the Irish market in the coming months due to global manufacturing delays in production and resupply of these products.

The following products are out of stock and will be resupplied in Q1 2019 (by the end of March 2019).

SINEMET 25/250MG 10X10 Tablets

SINEMET PLUS 25/100MG 10X10 Tablets

MSD would like to assure you that we are working to resolve this situation as soon as reasonably possible and anticipate these products will be resupplied in Q1 2019 (by the end of March 2019).

We recommend that any prescription for carbidopa/levodopa is written generically as supplies of alternative carbidopa-levodopa may be available from wholesalers. The Health Products Regulatory Authority (HPRA) has advised MSD that this alternative carbidopa/levodopa supply will be through the exempt medicines (unlicensed medicines) scheme.